Testing two antibody infusions during a pause in HIV medication
Treatments studied
Part of Infections clinical trials.
This study tests if two lab-made antibodies can keep HIV under control when people temporarily stop their daily HIV medication. Participants will pause their antiretroviral therapy (ART) for a period and be closely monitored, with the goal of potentially finding a way to take a break from daily pills.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You started HIV treatment within 90 days of your initial HIV diagnosis.
- You have been on HIV medication for at least 12 months and currently have an undetectable viral load.
- You are willing to temporarily stop your HIV medication under medical supervision and restart it when needed.
- Your weight is between 50 and 150 kg (about 110 to 330 pounds).
- You are in overall good health and meet basic lab criteria for blood counts, liver, and kidney function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs, baricitinib and sirolimus, alone or together, to see if they can help control HIV after you stop your usual HIV medications for a short time. The goal is to see if these drugs can keep the virus from rebounding.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This study tests a new combination of two drugs to see if they can reduce the 'hidden' HIV that stays in your body even when you're on regular HIV treatment. The goal is to work toward a cure, not just control.
This trial tests whether giving two powerful HIV-fighting antibodies (called broadly neutralizing monoclonal antibodies) along with starting standard HIV medications soon after infection can help control the virus without needing daily pills. If successful, it might allow people to take a 'treatment pause' while keeping their immune system healthy.
This study is testing three experimental antibodies (ePGT121v1-LS, PGDM1400LS, and VRC07-523LS) that may help prevent HIV. It’s looking at their safety and how long they stay in the body. Healthy volunteers without HIV can join.
This Phase 1 trial tests two new HIV vaccines (DV700P-RNA and DV701B1.1-RNA) combined with a monitored break from HIV medications in people with well-controlled HIV. The goal is to see if this approach safely strengthens the immune system's ability to fight HIV.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.